Dow Rises 30 Points; Crude Oil Down 2%
U.S. stocks traded mixed toward the end of trading, with the Dow Jones gaining around 30 points on Monday.
Nasdaq Dips 150 Points; Gold Down 2%
U.S. stocks pared gains midway through trading, with the Dow Jones dropping more than 100 points on Monday.
Why Applied DNA Sciences Shares Are Trading Higher By Around 65%, Here Are 54 Stocks Moving In Monday’s Mid-Day Session
Gainers
Applied DNA Sciences, Inc. (NASDAQ: APDN) shares jumped 64.5% to $2.03 after the company announced it has received its largest single purchase order for LinearDNA™ valued above the mid-six-figures.
US Stocks Mixed; Dow Rises Over 100 Points
U.S. stocks traded mixed this morning, with the Dow Jones gaining more than 100 points on Monday.
FDA Approves scPharmaceuticals’ Self-Administered Med For Congestion in Chronic Heart Failure
The FDA has approved scPharmaceuticals Inc’s (NASDAQ:SCPH) Furoscix (furosemide injection), a proprietary formulation of furosemide delivered via an On-Body Infusor for…
scPharmaceuticals Announces FDA Approval Of FUROSCIX
BURLINGTON, Mass., Oct. 10, 2022 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of
AstraZeneca-Merck’s Prostate Cancer Combo Drug, 3rd Try For scPharma, 3 FDA Panel Decisions And More: October’s Key PDUFA Catalysts Biotech Investors Must Know
Most FDA decisions scheduled for September yielded positive results, but there were stray disappointments as well. Seven new molecular entities, or NMEs, were approved during the month, taking the total NME approvals for the year to 24. This is far less than the 40 approvals received by the same time last year.
SVB Leerink Maintains Market Perform on scPharmaceuticals, Raises Price Target to $6
SVB Leerink analyst Roanna Ruiz maintains scPharmaceuticals (NASDAQ:SCPH) with a Market Perform and raises the price target from $5 to $6.
scPharmaceuticals Shares Are Trading High Following FDA’s Acceptance of NDA for FUROSCIX
scPharmaceuticals Inc. (NASDAQ: SCPH) announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of the drug candidate FUROSCIX, for the treatment of congestion in patients with worsening heart failure.
scPharmaceuticals Inc. Announces Resubmission Of FUROSCIX New Drug Application
scPharmaceuticals Inc. (NASDAQ:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care, and reduce